Abstract | INTRODUCTION AND AIM: MATERIALS AND METHODS: We included all 239 HTs performed in our center from 1989 to 2002. We divided patients into those who received gancyclovir treatment (prophylaxis, pre-emptive therapy, or for cytomegalovirus infection) versus those who did not receive this agent at any time during follow-up (88 vs 151 patients). The statistical methods were Student's t and chi-square tests. RESULTS: There were no differences in the baseline characteristics of the patients--gender, recipient age, etiology leading to HT, diabetes, and dyslipidemia--except for a higher rate of hypertension among the group who did not receive gancyclovir (73.7 vs 60.2%; P=.03). None of the 7 patients who developed lymphomas during the follow-up received gancyclovir (0 vs 4.6%; P=.040). CONCLUSIONS:
Antivirals may have a relevant role to neutralize potential neoplastic effects (especially lymphomas) associated with the use of OKT3 induction therapy.
|
Authors | I J Sánchez-Lázaro, L Almenar, L Martínez-Dolz, J Agüero, F Buendía, J Navarro, R Raso, A Salvador |
Journal | Transplantation proceedings
(Transplant Proc)
Vol. 42
Issue 8
Pg. 3206-7
(Oct 2010)
ISSN: 1873-2623 [Electronic] United States |
PMID | 20970653
(Publication Type: Journal Article)
|
Copyright | Copyright © 2010 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Antiviral Agents
- CD3 Complex
- Ganciclovir
|
Topics |
- Antibodies, Monoclonal
(immunology)
- Antiviral Agents
(pharmacology, therapeutic use)
- CD3 Complex
(immunology)
- Ganciclovir
(pharmacology, therapeutic use)
- Heart Transplantation
(adverse effects)
- Humans
- Lymphoma
(etiology, prevention & control)
|